Format

Send to

Choose Destination
Vaccine. 2007 Sep 27;25 Suppl 2:B24-34. Epub 2007 Jun 6.

Plasmid DNA and viral vector-based vaccines for the treatment of cancer.

Author information

1
Oxxon Therapeutics Ltd., 2nd Floor Florey House, 3 Robert Robinson Avenue, Oxford Science Park, Oxford OX4 4GP, UK.

Abstract

Plasmid DNA and viral vector-based cancer vaccines have many inherent features that make them promising cancer vaccine candidates. This review focuses on the use of plasmid DNA and viral vector vaccines to deliver tumour-specific antigens to induce a tumour-specific immune response. Examples of different antigen delivery systems that have been tested in recent clinical trials are summarised and advantages and disadvantages of a number of delivery systems and approaches are discussed. Finally, an outlook on how plasmid DNA and viral vectors might be developed further as cancer vaccines is provided.

PMID:
17698262
DOI:
10.1016/j.vaccine.2007.05.030
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center